Presidente Derqui

Researchers are studying multiple myeloma, a type of blood cancer, to see if the drug elranatamab, alone or combined with daratumumab, can offer more benefits compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone. This Phase 3 clinical trial focuses on people who have already been treated for multiple myeloma, including with lenalidomide. The study also evaluates the safety and activity of elranatamab with daratumumab and assesses infection protection measures for participants. The trial has three parts. Part 1 tests different doses of elranatamab combined with daratumumab to check safety and activity. In Part 2, participants are randomly assigned to one of three groups elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 examines how increased infection prevention affects those treated with elranatamab alone or with daratumumab. Treatments are given until the disease worsens, side effects become unacceptable, or participants choose to stop. Participants will be monitored for side effects, disease progression, and overall response using standardized criteria from the International Myeloma Working Group. Safety is closely watched, especially in early treatment phases, and quality of life is assessed with questionnaires. Outcome measures include progression-free survival, response rates, adverse events, and lab results. Participant involvement may last up to 51 months with regular evaluations during the study.